Sorrento Submits EUA to the US FDA for its COVI-TRACK Test to Detect COVID-19

 Sorrento Submits EUA to the US FDA for its COVI-TRACK Test to Detect COVID-19

Sorrento Submits EUA to the US FDA for its COVI-TRACK Test to Detect COVID-19

Shots:

  • Sorrento has reported that its EUA is under review at the US FDA for its COVI-TRACK in vitro diagnostic test kit for the detection of IgG and IgM Abs in sera of patients exposed to the SARS-CoV-2 virus
  • Following the issuance of an EUA, the COVI-TRACK test will be available for distribution to clinical testing sites nationwide. The assay develops three clear lines that confirm the assay validity and the qualitative detection & differentiation of IgM and IgG Abs to the COVID-19
  • Sorrento has secured manufacturing capacity to ramp up the production of up to 5M test kits/ month with the availability of results in ≤8mins. The assay showed specificity > 97% and diagnostic sensitivity of > 94% in an analytical validation

Click here to read full press release/ article | Ref: Sorrento | Image: Pharmaworld

Related News: Sorrento Collaborates with Mount Sinai Health System to Develop COVI-SHIELD Antibody Cocktail Targeting COVID-19

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post